Peptide Bio IndexEvidence first. Hype last.
⌕

MOTS-C Mechanisms and Metabolic Research

Written by

in

Peptide Research Overviews
PBIPeptide Bio Index Editorial DeskSource-labeled research summary
Source-limited10 min readUpdated Sep 3, 2026
Jump to a section
  1. Molecular identity and cellular trafficking
  2. Core biochemical mechanisms implicated in metabolic regulation
  3. Preclinical metabolic phenotypes and tissue specificity
  4. Translational signals, human observations, and clinical development
  5. Emerging non‑metabolic roles and biomarker potential
  6. Reported study-design details from cited sources
  7. Limitations and research gaps
  8. Documentation checklist
  9. Related research supplies
  10. More MOTS-c research
  11. Sources and references

Disclosure: Peptide Bio Index is affiliated with SourcePoint Research and may earn from qualifying purchases or affiliate links.

This article summarizes published research and reported study designs. It is not medical advice, dosing guidance, or a personal-use recommendation.

Source-limited research note: The reviewed sources were incomplete, ambiguous, or insufficient for a normal article. This page labels missing details rather than guessing.

This deep dive summarizes mechanistic and metabolic research on the mitochondrial‑derived peptide MOTS‑c, focusing on molecular identity, intracellular signaling and transcriptional roles, preclinical metabolic outcomes, early translational signals, and notable gaps in human interventional evidence as reflected in the reviewed sources.

Molecular identity and cellular trafficking

MOTS‑c is a 16–amino‑acid mitochondrial‑derived peptide encoded within a short open reading frame of the mitochondrial 12S rRNA region; it is detectable in tissues and plasma with reported decreases in circulating levels with age. [S1] [S2]

Under metabolic stress, MOTS‑c translocates from mitochondria to the nucleus where it regulates nuclear gene expression, indicating a mode of mitonuclear communication. [S6]

Core biochemical mechanisms implicated in metabolic regulation

Mechanistic studies report that MOTS‑c can inhibit the folate cycle and tethered de novo purine biosynthesis, a perturbation that activates AMPK signaling; AMPK activation is presented as a central pathway linking MOTS‑c to improved cellular metabolic homeostasis. [S2] [S8]

Separate work identifies casein kinase 2 (CK2) as a direct and functional target of MOTS‑c: MOTS‑c binds CK2 and modulates its activity in a tissue‑specific manner, with evidence that CK2 activity is required for at least some MOTS‑c effects on muscle glucose uptake and atrophy prevention. [S7]

Nuclear actions of MOTS‑c include regulation of genes bearing antioxidant response elements (AREs) and interaction with stress‑responsive transcription factors such as NRF2; one rat study reported direct MOTS‑c interaction with promoters of antioxidant genes (e.g., HMOX1, NQO1) during ischemia‑reperfusion contexts. [S6] [S4]

Preclinical metabolic phenotypes and tissue specificity

Multiple preclinical reports in rodents indicate MOTS‑c administration or induction improves systemic metabolic phenotypes: treatment prevented age‑dependent and high‑fat‑diet‑induced insulin resistance and reduced diet‑induced obesity in mice, and altered plasma metabolite profiles consistent with enhanced fatty‑acid oxidation and insulin sensitivity. [S2] [S10] [S9]

In specialized models, MOTS‑c administration improved metabolic outcomes: daily administration during pregnancy in a gestational diabetes mouse model alleviated hyperglycemia, improved insulin sensitivity and glucose tolerance, and reduced adverse reproductive outcomes; separate mouse studies report protection from skeletal muscle atrophy and enhanced muscle glucose uptake that depend on CK2 activity. [S3] [S7]

Evidence also points to tissue‑specific responses: systemic MOTS‑c was reported to bind CK2 in both adipose and muscle, yet activate CK2 in muscle while suppressing it in fat, and endogenous MOTS‑c expression is inducible by exercise with reported benefits for muscle homeostasis and age‑related physical decline. [S9] [S7]

Translational signals, human observations, and clinical development

Human observational data show circulating MOTS‑c levels associate with indices of insulin sensitivity in some cohorts (for example, an association in lean but not obese individuals) and circulating levels reportedly decline with age, supporting links between MOTS‑c and metabolic status in humans. [S11] [S1]

Clinical development includes a trial registry record for a MOTS‑c analog (CB4211) evaluated in a randomized, placebo‑controlled Phase 1a/1b study with a 28‑day nonalcoholic fatty liver disease (NAFLD) cohort; the registry entry indicates study completion in 2021 but contained no posted results in the reviewed excerpt. [S12]

Narrative reviews of peptide therapeutics note expanding off‑label and gray‑market use of unapproved peptides including MOTS‑c, and caution that rigorous human safety data are scarce for many unapproved compounds. [S5]

Emerging non‑metabolic roles and biomarker potential

A rat ischemia‑reperfusion study reported endothelial upregulation of MOTS‑c that preserved barrier function and reduced oxidative stress, and found that early postoperative increases in serum MOTS‑c predicted acute respiratory distress syndrome (ARDS) incidence after cardiopulmonary bypass with improved discriminative performance in multivariate models (reported AUC = 0.885 in the reviewed excerpt). [S4]

Mechanistically, those findings align with nuclear targeting of antioxidant gene programs (ARE‑containing promoters) and suggest both a tissue‑protective signaling role and potential utility as a dynamic biomarker in acute injury settings, though evidence is currently preclinical plus limited clinical correlational data. [S6] [S4]

Reported study-design details from cited sources

The following table summarizes protocol details reported in cited studies. These details are provided as literature context only and are not recommendations or instructions.

Source Study Type Model / Subject Amount Reported Route Reported Frequency Duration Notes
[S2] animal study (mouse) mouse not reported in the reviewed source not reported in the reviewed source not reported in the reviewed source not reported in the reviewed source Reported prevention of age‑dependent and high‑fat‑diet‑induced insulin resistance and diet‑induced obesity; mechanistic link to folate‑cycle inhibition and AMPK activation described.
[S3] animal study (GDM mouse model) mouse (gestational diabetes model) not reported in the reviewed source not reported in the reviewed source daily during pregnancy MOTS‑c administration during pregnancy alleviated hyperglycemia, improved insulin sensitivity and glucose tolerance, reduced offspring birth weight and death in the GDM model; also reported protection of pancreatic β‑cells from STZ injury.
[S4] animal study (rat) rat (lung ischemia‑reperfusion models) not reported in the reviewed source not reported in the reviewed source not reported in the reviewed source not reported in the reviewed source Endothelial MOTS‑c upregulation associated with barrier preservation and reduced oxidative stress; exogenous MOTS‑c administration attenuated lung injury and reduced mortality in rats; serum MOTS‑c changes within 24 h post‑CPB associated with ARDS prediction (AUC reported).
[S6] cellular and molecular study cell lines / metabolic stress models not reported in the reviewed source not applicable not reported in the reviewed source not reported in the reviewed source MOTS‑c translocates to the nucleus under metabolic stress and regulates nuclear gene expression in an AMPK‑dependent manner, including genes with antioxidant response elements and interaction with NRF2.
[S7] animal study (mouse) mouse not reported in the reviewed source not reported in the reviewed source not reported in the reviewed source not reported in the reviewed source Systemic MOTS‑c administration prevented skeletal muscle atrophy and enhanced muscle glucose uptake in mice; effects were blunted by CK2 suppression; a natural K14Q MOTS‑c variant had reduced CK2 binding and altered disease associations in humans.
[S12] clinical trial registry (Phase 1a/1b) healthy non‑obese subjects and subjects with NAFLD not reported in the reviewed source not reported in the reviewed source not reported in the reviewed source 28 days (NAFLD cohort) Registry for CB4211 (a MOTS‑c analog) describes randomized, placebo‑controlled evaluation including a 28‑day NAFLD cohort; record indicated study completion in 2021 with no posted results in the reviewed excerpt.

Limitations and research gaps

  • Most mechanistic and efficacy data in the reviewed sources are preclinical (cellular and rodent models); randomized human interventional data are not available in the reviewed excerpts.
  • Protocol specifics (dose amount, administration route, precise dosing frequency, and pharmacokinetics) are often not reported in the reviewed excerpts; where absent the protocol table explicitly notes this.
  • Observational human correlations (circulating MOTS‑c vs metabolic indices) are cohort‑dependent and may not generalize across populations (e.g., differences between lean and obese cohorts).
  • A clinical candidate registry entry (CB4211) exists but the reviewed record contained no posted results, limiting interpretation of translational progress.

Documentation checklist

  • MOTS-c is a 16–amino‑acid peptide encoded in the mitochondrial 12S rRNA region — verify genomic origin before citing.
  • Key cellular mechanisms reported: nuclear translocation during metabolic stress, AMPK activation via folate‑cycle disruption, and direct binding to CK2 — consult primary mechanistic reports for context.
  • Preclinical metabolic outcomes (mouse/rat) include improved insulin sensitivity and resistance to diet‑induced obesity, but human interventional data are not available in the reviewed sources.
  • Human observational evidence links circulating MOTS‑c levels to metabolic status in some cohorts (e.g., lean adults), but associations may not hold in all populations (e.g., obesity).
  • A clinical candidate (CB4211, a MOTS‑c analog) completed a Phase 1a/1b registry entry; no results were posted on the registry record in the reviewed excerpt.
  • When citing therapeutic or protocol details, use study‑level design fields (amount, route, frequency, duration) from original reports; many reviewed excerpts do not report those fields.
  • Peptide storage log templates and cold‑chain documentation (vendor‑neutral)
  • Laboratory sample labeling and inventory sheets for frozen peptide reagents
  • General laboratory protein/peptide assay documentation (e.g., ELISA/Western blot protocol templates)
  • Laboratory freezer temperature monitoring and alarm procedure documents

Research organization supplies: Common tools used for research documentation workflows may include lab notebooks, label makers, sample storage boxes, inventory stickers, and temperature log sheets.

Paid-link disclosure: Peptide Bio Index may earn a commission from qualifying purchases. As an Amazon Associate I earn from qualifying purchases.

Batch and inventory labeling

Phomemo M110 Label and Barcode Printer

A compact thermal label printer for inventory identifiers, storage-box labels, batch references, and document-folder organization.

View on Amazon (paid link)

Label-printer refill

Phomemo M110 White Replacement Labels

White 1.57 × 0.78 inch replacement labels for compatible Phomemo printers. Confirm printer and label-size compatibility before ordering.

View on Amazon (paid link)

Product listings, specifications, and availability can change. Review the current Amazon listing and manufacturer instructions before ordering. These links are for research organization and compatible surface/equipment-cleaning workflows, not personal-use guidance.

Research Supply Note: For research-use-only sourcing, review current SourcePoint Research inventory and batch documentation at SourcePointResearch.com. Peptide Bio Index is affiliated with SourcePoint Research.

More MOTS-c research

Sources and references

  1. [S1] Zheng Y, Wei Z, Wang T. MOTS-c: A promising mitochondrial-derived peptide for therapeutic exploitation.. Frontiers in endocrinology. 2023. PMID: 36761202. DOI: 10.3389/fendo.2023.1120533
  2. [S2] Lee C, Zeng J, Drew BG, Sallam T, Martin-Montalvo A, Wan J. The mitochondrial-derived peptide MOTS-c promotes metabolic homeostasis and reduces obesity and insulin resistance.. Cell metabolism. 2015. PMID: 25738459. DOI: 10.1016/j.cmet.2015.02.009
  3. [S3] Yin Y, Pan Y, He J, Zhong H, Wu Y, Ji C. The mitochondrial-derived peptide MOTS-c relieves hyperglycemia and insulin resistance in gestational diabetes mellitus.. Pharmacological research. 2022. PMID: 34798268. DOI: 10.1016/j.phrs.2021.105987
  4. [S4] Li X, Zhan F, Qiu G, Lu P, Shen Z, Qi Y. MOTS-c attenuates lung ischemia-reperfusion injury via MYH9-Dependent nuclear translocation and transcriptional activation of antioxidant genes.. Redox biology. 2025. PMID: 40403491. DOI: 10.1016/j.redox.2025.103681
  5. [S5] Mendias CL, Awan TM. Safety and Efficacy of Approved and Unapproved Peptide Therapies for Musculoskeletal Injuries and Athletic Performance.. Sports medicine (Auckland, N.Z.). 2026. PMID: 41966639. DOI: 10.1007/s40279-026-02437-0
  6. [S6] Kim KH, Son JM, Benayoun BA, Lee C. The Mitochondrial-Encoded Peptide MOTS-c Translocates to the Nucleus to Regulate Nuclear Gene Expression in Response to Metabolic Stress.. Cell metabolism. 2018. PMID: 29983246. DOI: 10.1016/j.cmet.2018.06.008
  7. [S7] Kumagai H, Kim SJ, Miller B, Zempo H, Tanisawa K, Natsume T. MOTS-c modulates skeletal muscle function by directly binding and activating CK2.. iScience. 2024. PMID: 39559755. DOI: 10.1016/j.isci.2024.111212
  8. [S8] Gao Y, Wei X, Wei P, Lu H, Zhong L, Tan J. MOTS-c Functionally Prevents Metabolic Disorders.. Metabolites. 2023. PMID: 36677050. DOI: 10.3390/metabo13010125
  9. [S9] MOTS-c is an exercise-induced mitochondrial-encoded regulator of age-dependent physical decline and muscle homeostasis. primary literature
  10. [S10] The mitochondrial-derived peptide MOTS-c is a regulator of plasma metabolites and enhances insulin sensitivity. primary literature
  11. [S11] Plasma MOTS-c levels are associated with insulin sensitivity in lean but not in obese individuals. primary literature
  12. [S12] A Phase 1a/1b Study of CB4211 in Healthy Non-obese Subjects and Subjects With Nonalcoholic Fatty Liver Disease (NCT03998514). trial registry

Peptide Bio Index is affiliated with SourcePoint Research. Articles may link to SourcePointResearch.com and third-party affiliate products. As an Amazon Associate, Peptide Bio Index earns from qualifying purchases. Content is educational and research-literature focused only and is not medical advice, dosing guidance, or a personal-use recommendation.

More posts